New study explores Kidney-Friendly hepatitis b drug for transplant patients
NCT ID NCT07267208
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial will enroll 82 stable liver transplant recipients with chronic hepatitis B to see if switching to entecavir orally disintegrating tablets (ETV-ODT) is safe and helps preserve kidney function. Participants will take the drug daily for 48 weeks, and researchers will monitor changes in kidney function and any signs of hepatitis B returning. The study aims to offer a more convenient treatment option that may be gentler on the kidneys.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Entecavir orally disintegrating tablets (ETV-ODT)
What this could lead to
If successful, this could show that switching to entecavir ODT is safe and may help protect kidney function in liver transplant patients with hepatitis B.
What could go wrong
This is a small, early-phase study with only 82 participants, so results may not apply to all patients. It focuses on kidney function, not on curing hepatitis B, and there is a risk of HBV recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact